Ixamib 2.3mg cap (Ixazomib Capsule) 2.3

Ixamib 2.3mg cap contains ixazomib, a prescription medicine used in combination with other drugs for certain types of cancer. It belongs to a class of medications called proteasome inhibitors. Always follow healthcare provider guidance when using this capsule.

Strength

2.3

Manufacturer / TM Owner

Azista Bhutan Healthcare Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ixamib 2.3mg cap is used to treat multiple myeloma in adults when combined with lenalidomide and dexamethasone. It may also be prescribed for relapsed or refractory multiple myeloma. This medication helps slow or stop cancer cell growth by interfering with proteasomes in cells. Patients often ask, what is Ixamib 2.3mg cap used for in cancer treatment.

Side Effects

Ixamib 2.3mg cap may cause side effects such as nausea, diarrhea, or low blood cell counts. Some people experience fatigue, rash, or peripheral neuropathy. These effects vary by individual and should be monitored by a healthcare professional. Regular check-ups help manage any changes during treatment.

Precautions & Warnings

Store Ixamib 2.3mg cap at room temperature away from moisture and heat. Keep the medication in its original blister pack until ready to use. Always handle capsules with dry hands to avoid moisture exposure. Do not crush, chew, or open the capsule unless instructed by a doctor.

Avoid Interactions

Ixamib 2.3mg cap may interact with other medications, including strong CYP3A inducers or inhibitors. Avoid grapefruit products unless approved by a healthcare provider. Some drugs, like certain antifungals or antibiotics, can affect ixazomib levels. Always inform your doctor about all medicines and supplements you take.

Frequently Asked Questions

Ixamib 2.3mg cap is used to treat multiple myeloma in adults when combined with other cancer medications.

Take Ixamib 2.3mg cap exactly as prescribed by your doctor, usually once a week on the same day.

Common side effects include nausea, diarrhea, low blood cell counts, fatigue, and rash.

Ixamib 2.3mg cap can be taken with or without food, but it should be swallowed whole with water.

Ixamib 2.3mg cap is a proteasome inhibitor used in cancer therapy, not a traditional chemotherapy agent.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.